Time to go All-In on Celsion?
Celsion (CLSN) is a great story stock. It recently announced their Phase III trial results for liver cancer will be released by the end of January 2013. This will be a top-line release of a multinational, double-blind, placebo-controlled study of primary liver cancer. The results could make or break the company as its future pipeline is dependent on ThermoDox succeeding.
This upcoming catalyst is likely to have a huge impact on the company's valuation. The company has a current market cap of $287 million, but this will likely be drastically different by the end of the month. The CEO of Celsion has stated that this liver cancer treatment will have the potential to generate yearly revenues of $1 billion.
Mastery Bottom Line
Look for a good entry point before betting the farm on CLSN. Shares could dip down to touch the 50 day MA due to some investors not wanting to risk holding through the FDA results. A $7 - $7.50 share price would provide a great buying opportunity.
Best of the Blogs
Scanning and identifying the best blog entries every hour
- Goldman Sachs Is Buying Carl Icahn's "High Yield Bond Bubble" | ZeroHedge
- How The Federal Reserve Is Purposely Attacking Savers | ZeroHedge
- Oil Prices Continue to Define Geopolitics | Financial Sense
- Central Banker Admits Central Bank Policy Leads To Wealth Inequality | ZeroHedge
- Morning Motivation | iBankCoin.com
- High Yield Corporate Algo Gone Wild | iBankCoin.com
- Five Stocks Feeding Off the Big $CAT Today | iBankCoin.com
The most relevant financial news and articles from the Internets
- US Stock Futures Fall After Ebola Case Confirmed In New York City (DIA, SPY, QQQ, TLT... | Business Insider
- Dicker: With Low Oil Prices, Which Companies Should You Buy? | TheStreet.com
- Caterpillar Crushes Expectations And The Stock Is Going Nuts (CAT) | Business Insider
- Laptop Computer Reviews - BusinessWeek | BusinessWeek
- Kroger Is Suddenly Whole Foods' Biggest Threat | Business Insider
- TIM COOK: ‘It’s Just A Matter Of... | Business Insider
- Suze Orman, Debit-Card Dealer | BusinessWeek